Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737636 | 0.85 | SIGMAR1 (0.37) | SIGMAR1LMNABLM | |
| SCHEMBL24209562 | 0.78 | ARG1 (0.49) | — | |
| SCHEMBL18260436 | 0.77 | ACHE (0.45) | — | |
| SCHEMBL6071126 | 0.76 | GAA (0.40) | LMNABLM | |
| SCHEMBL28556951 | 0.76 | BACE1 (0.37) | HTR2AHRH1HTR2BEGFRLMNA | |
| SCHEMBL7376873 | 0.71 | HTR1A (0.35) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| SCHEMBL7739975 | 0.71 | TSHR (0.40) | HTR2AHRH1LMNABLM | |
| SCHEMBL4012265 | 0.69 | HTR2A (0.42) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| SCHEMBL6716717 | 0.69 | EPHX2 (0.37) | LMNABLM | |
| SCHEMBL306308 | 0.69 | EPHX2 (0.37) | LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152670-A1 | Novel aminoindanes | CURRY KENNETH (CA) | 2004-08-05 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| EP-1194399-A2 | NOVEL AMINOINDANES | Prescient Neuropharma Inc. (CA) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002340-A2 | NOVEL AMINOINDANES | IGT PHARMA INC. (CA) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152670-A1 | Novel aminoindanes | GRM1, GRM2, GRIN1 | GRM2 2/4885GRM5 9/4885GRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.